glp 1 and autoimmune hepatitis Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case–control study | Cardiovascular Diabetology Gut–Liver–Pancreas Axis Crosstalk in Health

A meta-analysis by Faraone and Buitelaar (2010) pooling data from multiple randomized controlled trials found that amphetamine-based medications had a modestly larger mean effect size (SMD 0.99) for ADHD symptom reduction compared to methylphenidate-based medications (SMD 0.78) [6]

Since this may be expensive, though, it may create a barrier for companies to explore this option

Its no secret that GLP-1 drugs like Ozempic and Wegovy are dominating headlines and prescriptions

Systematic search of the literature yielded 280 pre-clinical/mechanistic studies and 96 clinical studies eligible for this review

Prescription GLP-1 medications have changed the conversation around obesity, type 2 diabetes and metabolic health